• $1B of 1.7% notes due 2019 • $1B of 2.2% notes due 2021 • $1.75B of 3.0% notes due 2026 • $1B 4.0% notes due 2036 • $1.25B of 4.125% notes due 2046
Up to $3.25B of the proceeds from the new bonds will be used to retire (via a tender offer) PFE’s existing bonds due in 2019. That leaves at least $2.75B for “general corporate purposes,” which likely means M&A.
‡ Relative to “unaffected” share price in cases where a buyout offer or auction was made public; excludes CVRs unless otherwise specified.
* Adjusted for cash/debt on acquired company’s balance sheet; excludes CVRs unless otherwise specified.
® Reverse merger; premium not calculable.
j Excluding CVR potentially worth $49.84/sh.
k Premium relative to 3/30/16 close.
m Merged company to be named Novelion.
n Premium relative to 2/24/15 (before leak of buyout bidding war).
p Premium relative to 8/18/14 (before speculation re AGN takeover).
q Premium relative to 4/10/14 (before Pershing Sq accumulation).
s Premium excludes contingent fees and is calculated from 12/13/13 close, the day before ENDP offer.
t For 42% of company not already owned.
u Includes $1.7B assumption of debt; premium relative to 3/27/12 close, when Bloomberg reported BMY bid. AZN pays BMY $3.4B to put AMLN’s portfolio into 50/50 JV.
v Excluding CVR of $4-14/sh; premium relative to 7/22/10 close.
w For 44% of DNA not already owned.
x Price includes entire deal in three stages; 17% premium is the blended avg price of NVS’ purchases ($164) relative to ACL’s market price 4/4/08 immediately prior to announcement of first stage of deal.
y Includes $0.45/sh of contingent payments.
z Liquidated by Deerfield following failed merger with Archemix.